Trexquant Investment LP Purchases 34,841 Shares of LeMaitre Vascular, Inc. $LMAT

Key Points

• Trexquant Investment LP significantly increased its stake in LeMaitre Vascular by 574.4%, acquiring an additional 34,841 shares during the first quarter, bringing its total ownership to 40,907 shares valued at approximately $3.4 million.
• Institutional investors now own 84.64% of LeMaitre Vascular's shares, with other notable increases in stakes from firms like Northern Trust Corp and Invesco Ltd.
• LeMaitre Vascular reported $0.60 earnings per share for the most recent quarter, beating expectations and reflecting a 15.0% increase in revenue compared to the previous year.

Trexquant Investment LP lifted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 574.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,907 shares of the medical instruments supplier's stock after purchasing an additional 34,841 shares during the period. Trexquant Investment LP owned 0.18% of LeMaitre Vascular worth $3,432,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in LMAT. Hsbc Holdings PLC lifted its position in shares of LeMaitre Vascular by 43.5% during the fourth quarter. Hsbc Holdings PLC now owns 3,861 shares of the medical instruments supplier's stock valued at $358,000 after purchasing an additional 1,170 shares in the last quarter. Northern Trust Corp lifted its position in shares of LeMaitre Vascular by 5.1% during the fourth quarter. Northern Trust Corp now owns 327,815 shares of the medical instruments supplier's stock valued at $30,205,000 after purchasing an additional 15,843 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of LeMaitre Vascular by 3.1% during the fourth quarter. BNP Paribas Financial Markets now owns 28,703 shares of the medical instruments supplier's stock valued at $2,645,000 after purchasing an additional 874 shares in the last quarter. Bank of America Corp DE lifted its position in shares of LeMaitre Vascular by 32.8% during the fourth quarter. Bank of America Corp DE now owns 61,752 shares of the medical instruments supplier's stock valued at $5,690,000 after purchasing an additional 15,250 shares in the last quarter. Finally, Balyasny Asset Management L.P. bought a new stake in LeMaitre Vascular in the fourth quarter worth about $3,090,000. 84.64% of the stock is owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director David B. Roberts sold 10,815 shares of the business's stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $92.39, for a total value of $999,197.85. Following the completion of the sale, the director directly owned 17,976 shares in the company, valued at approximately $1,660,802.64. The trade was a 37.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 100,000 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $93.51, for a total transaction of $9,351,000.00. Following the completion of the sale, the chief executive officer owned 1,727,003 shares of the company's stock, valued at approximately $161,492,050.53. The trade was a 5.47% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 120,815 shares of company stock valued at $11,280,206. Insiders own 9.50% of the company's stock.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $0.24 during trading hours on Monday, hitting $97.25. The company's stock had a trading volume of 11,053 shares, compared to its average volume of 189,020. The company has a market cap of $2.20 billion, a price-to-earnings ratio of 47.10, a PEG ratio of 2.51 and a beta of 0.79. The company has a debt-to-equity ratio of 0.46, a current ratio of 13.96 and a quick ratio of 11.74. The business has a 50 day simple moving average of $88.64 and a two-hundred day simple moving average of $86.10. LeMaitre Vascular, Inc. has a 52-week low of $71.42 and a 52-week high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.03. The firm had revenue of $63.15 million during the quarter, compared to the consensus estimate of $62.48 million. LeMaitre Vascular had a net margin of 20.08% and a return on equity of 13.67%. The company's revenue was up 15.0% on a year-over-year basis. During the same quarter last year, the company earned $0.52 earnings per share. LeMaitre Vascular has set its Q3 2025 guidance at 0.540-0.590 EPS. FY 2025 guidance at 2.230-2.370 EPS. On average, equities analysts expect that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, September 4th. Stockholders of record on Thursday, August 21st were issued a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date was Thursday, August 21st. LeMaitre Vascular's payout ratio is presently 38.83%.

Analyst Upgrades and Downgrades

Several analysts have commented on LMAT shares. Cantor Fitzgerald lifted their price objective on shares of LeMaitre Vascular from $92.00 to $95.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Barrington Research raised shares of LeMaitre Vascular from a "market perform" rating to an "outperform" rating and set a $95.00 price objective on the stock in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $97.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.